Quotient Sciences Launches as the New Global Identity for Quotient Clinical
News Nov 12, 2017
Credit: Quotient Sciences
Quotient Clinical announces its renaming to Quotient Sciences (Quotient), following the acquisitions of Co-Formulate, QS Pharma and SeaView Research. This new identity signifies a global footprint and an extended range of services, and symbolizes the commitment to ensuring a consistent and high-quality experience for customers.
With 700 employees and five operating sites across the United States and the United Kingdom, Quotient is focused on delivering a portfolio of innovative services encompassing formulation development, clinical trial and commercial manufacturing, and clinical pharmacology.
Quotient’s Translational Pharmaceutics® platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research, transforming the traditional industry approach of outsourcing to independent contract development and manufacturing organizations (CDMOs) and contract research organizations (CROs). Translational Pharmaceutics is proven to accelerate development timelines and reduce overall costs.
“We are excited about the future of Quotient Sciences,” said Mark Egerton, CEO, Quotient Sciences. “By integrating services typically found in disparate CDMOs and CROs, we break down barriers and support our customers to improve R&D productivity and accelerate the delivery of new medicines to patients around the world. We have a 30-year track record of service to a global customer base, including large multinational pharmaceutical companies to smaller virtual biotech organizations.”
When people take MDMA, the drug popularly known as ecstasy, a rush of serotonin, dopamine, and oxytocin makes people more interested than they would normally be in connecting and sharing with other people. Now, researchers have made the surprising discovery that a species of octopus considered to be asocial responds to MDMA in the same way.